A new study finds that one in three older men with benign prostatic hyperplasia (BPH) get little to no relief from tamsulosin, a widely used prostate drug. The double-blind trial suggests that lifelong prescribing may not be warranted for everyone — and that short empiric trials could help identify who actually benefits.
Tamsulosin is one of the most commonly prescribed drugs for lower urinary tract symptoms (LUTS) in older men with benign prostatic hyperplasia (BPH) — but a new study published in JAMA Network Open suggests it doesn't work the same for everyone. Researchers at UCSF ran a double-blind randomized trial with 31 men aged 55–80, cycling them through tamsulosin and placebo periods to measure individual treatment responses. The results? Nearly 37% showed minimal or no symptom benefit from the drug.
On average, men reported about 3 fewer daily symptom points on tamsulosin compared to placebo — a modest benefit overall. But the spread was wide: 13% had a strong response, 37% a moderate one, and another 13% couldn't tolerate switching to placebo at all. Nearly all participants (92%) reported at least one day of a possible adverse drug reaction.
By the Numbers:
Why it matters: These findings challenge the default of lifelong tamsulosin therapy for all BPH patients. Clinicians may want to consider short empiric trials to identify true responders — and deprescribe in those who aren't benefiting.
